A recent study from a large cohort of patients with AML (n = 77) demonstrated elevated levels of activated phospho-Jak2 (p-JAK2) in bone marrow samples which is associated with high white blood cell count, low platelet count, and shorter survival in patients with either de novo or secondary AML. This evidence concerns the gene JAK2 and acute myeloid leukemia.